As cited by the research report titled ‘U.S. Non-Invasive Prenatal Testing Market - Growth, Demand, Trends, Opportunity, Forecasts (2020-2027)’, available with MarketStudyReport, U.S. non-invasive prenatal testing market is projected to expand significantly over 2021-2027, generating revenues worth USD 2.2 billion by the end of the forecast duration.
 

Factors such as high risk of chromosomal abnormalities with growing maternal age, rising incidences of chromosomal aneuploidies among fetus, rising development of advanced testing solutions, and growing product awareness are majorly driving the U.S. non-invasive prenatal testing market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2915595/
 

Moreover, favorable reimbursement policies, rising preference towards using non-invasive techniques as compared to invasive methods are positively swaying the industry dynamics.
 

Based on the product and solution, U.S. non-invasive prenatal testing market is segmented into systems, consumables/kits, and software. Among these, consumables segment is likely to showcase lucrative growth through 2027, owing to factors like growing incidences of chromosomal abnormalities, rising the number of tests & products, and increase in approvals or licenses for assays.
 

Considering application range, the marketplace is categorized into trisomy detection, microdeletions syndrome, sex chromosomal abnormalities, and other applications. Among these, trisomy detection segment is poised to hold a substantial market share over the assessment period due to growing incidences of trisomies in babies.
 

Speaking of the end user ambit, the business space is divided into diagnostic laboratories, hospitals and academic & research institutes. Among these, diagnostic laboratories segment is anticipated to expand significantly over the estimated timeline, owing to increasing usage of NIPT services provided by diagnostic laboratories by gynecologists & patients and easy availability of well-equipped facility as well as trained laboratory technicians.
 

Moving on to method type, the industry space is classified into biochemical screening tests, ultrasound detection, and cell-free DNA screening. Among these, cell-free DNA screening segment is anticipated to expand with a highest CAGR during the projected timeframe, on account of technological advancements and growing company initiatives to develop new products.
 

Prominent players influencing U.S. non-invasive prenatal testing industry dynamics are Agilent Technologies Inc., PerkinElmer Inc., Progenity Inc., GenPath Diagnostics, Invitae Corporation, Centogene AG, Myriad Genetics Inc., Quest Diagnostics, Natera Inc., Illumina Inc., Ariosa Diagnostics (Roche), Yourgene Health plc, and Integrated Genetics (LabCorp).